Clinical trial NCT05232955 - References

Tourette Syndrome — Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI

Citation(s)

•   Albin RL, Mink JW
  Recent advances in Tourette syndrome research. Trends Neurosci. 2006 Mar;29(3):175-82. doi: 10.1016/j.tins.2006.01.001. Epub 2006 Jan 23.
•   Bourne JA
  SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001 Winter;7(4):399-414. doi: 10.1111/j.1527-3458.2001.tb00207.x.
•   Draper A, Stephenson MC, Jackson GM, Pepes S, Morgan PS, Morris PG, Jackson SR
  Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol. 2014 Oct 6;24(19):2343-7. doi: 10.1016/j.cub.2014.08.038. Epub 2014 Sep 25.
•   Forde NJ, Kanaan AS, Widomska J, Padmanabhuni SS, Nespoli E, Alexander J, Rodriguez Arranz JI, Fan S, Houssari R, Nawaz MS, Rizzo F, Pagliaroli L, Zilhao NR, Aranyi T, Barta C, Boeckers TM, Boomsma DI, Buisman WR, Buitelaar JK, Cath D, Dietrich A, Driessen N, Drineas P, Dunlap M, Gerasch S, Glennon J, Hengerer B, van den Heuvel OA, Jespersgaard C, Moller HE, Muller-Vahl KR, Openneer TJ, Poelmans G, Pouwels PJ, Scharf JM, Stefansson H, Tumer Z, Veltman DJ, van der Werf YD, Hoekstra PJ, Ludolph A, Paschou P
  TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. Front Neurosci. 2016 Aug 23;10:384. doi: 10.3389/fnins.2016.00384. eCollection 2016.
•   Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE
  Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 Aug;33(8):1272-1280. doi: 10.1002/mds.27457. Epub 2018 Sep 7.
•   Kaller S, Rullmann M, Patt M, Becker GA, Luthardt J, Girbardt J, Meyer PM, Werner P, Barthel H, Bresch A, Fritz TH, Hesse S, Sabri O
  Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1025-1032. doi: 10.1007/s00259-017-3645-0. Epub 2017 Feb 14.
•   Kanaan AS, Gerasch S, Garcia-Garcia I, Lampe L, Pampel A, Anwander A, Near J, Moller HE, Muller-Vahl K
  Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. Brain. 2017 Jan;140(1):218-234. doi: 10.1093/brain/aww285. Epub 2016 Dec 22.
•   Kwak C, Dat Vuong K, Jankovic J
  Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec;18(12):1530-3. doi: 10.1002/mds.10618.
•   Larsen B, Olafsson V, Calabro F, Laymon C, Tervo-Clemmens B, Campbell E, Minhas D, Montez D, Price J, Luna B
  Maturation of the human striatal dopamine system revealed by PET and quantitative MRI. Nat Commun. 2020 Feb 12;11(1):846. doi: 10.1038/s41467-020-14693-3.
•   Leckman JF
  Tourette's syndrome. Lancet. 2002 Nov 16;360(9345):1577-86. doi: 10.1016/S0140-6736(02)11526-1.
•   Lerner A, Bagic A, Simmons JM, Mari Z, Bonne O, Xu B, Kazuba D, Herscovitch P, Carson RE, Murphy DL, Drevets WC, Hallett M
  Widespread abnormality of the gamma-aminobutyric acid-ergic system in Tourette syndrome. Brain. 2012 Jun;135(Pt 6):1926-36. doi: 10.1093/brain/aws104. Epub 2012 May 10.
•   Maia TV, Conceicao VA
  Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account. Biol Psychiatry. 2018 Sep 1;84(5):332-344. doi: 10.1016/j.biopsych.2018.02.1172. Epub 2018 Mar 9.
•   Mink JW
  Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatr Neurol. 2001 Sep;25(3):190-8. doi: 10.1016/s0887-8994(01)00262-4.
•   Moller HE, Bossoni L, Connor JR, Crichton RR, Does MD, Ward RJ, Zecca L, Zucca FA, Ronen I
  Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. Trends Neurosci. 2019 Jun;42(6):384-401. doi: 10.1016/j.tins.2019.03.009. Epub 2019 Apr 29.
•   Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M
  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997 Feb 13;385(6617):634-6. doi: 10.1038/385634a0.
•   Singer HS, Morris C, Grados M
  Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses. 2010 May;74(5):862-7. doi: 10.1016/j.mehy.2009.11.028. Epub 2009 Dec 21.
•   Singer HS
  Treatment of tics and tourette syndrome. Curr Treat Options Neurol. 2010 Nov;12(6):539-61. doi: 10.1007/s11940-010-0095-4.
•   Tinaz S, Belluscio BA, Malone P, van der Veen JW, Hallett M, Horovitz SG
  Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging. Hum Brain Mapp. 2014 Dec;35(12):5834-46. doi: 10.1002/hbm.22588. Epub 2014 Jul 15.
•   Yoon DY, Gause CD, Leckman JF, Singer HS
  Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007 Apr 15;255(1-2):50-6. doi: 10.1016/j.jns.2007.01.069. Epub 2007 Mar 6.

Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI

Details for clinical trial NCT05232955